{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:01:56Z","timestamp":1788973316944,"version":"build-2803163510"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017959","name":"Health Commission of Hebei Province","doi-asserted-by":"publisher","award":["No. 20242271"],"award-info":[{"award-number":["No. 20242271"]}],"id":[{"id":"10.13039\/100017959","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Aims<\/jats:title>\n<jats:p>To investigate whether optimal glycemic control is associated with all-cause mortality, cardiovascular disease mortality, diabetes-related mortality, cancer-related mortality, and complications among individuals with early-onset and late-onset T2D.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a retrospective cohort study using data from the U.S. National Health and Nutritional Examination Survey (NHANES)1999\u20132818. Optimal glycemic control was defined as HbA1c&lt;7%, and poor glycemic control as HbA1c\u22659%. Mortality and underlying causes of death were ascertained by linkage to national death records through 31 December 2019. Cox proportional hazards regression models adjusted for age, sex, race, education, body mass index (BMI), hypertension, smoking status, alcohol consumption, and physical activity were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between HbA1c levels and mortality. Logistic regression models with the same covariates were employed to calculate odds ratios (ORs) and 95% CIs for complications, supplemented by sensitivity analyses to evaluate the robustness of the findings.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Among the 5946 participants with diabetes, 18.8% were classified as having early-onset T2D (aged\u2009&lt;\u200940 years), 28.7% as having late-onset T2D (aged\u2009\u2264\u200960 years), and 52.5% had average-onset T2D. For individuals with early-onset T2D, the poorly controlled group (HbA1c\u22659%) had HRs of 2.00 (95% CI, 1.30\u20133.09; P\u2009=\u20090.002) for all-cause mortality and 10.04 (95% CI, 2.57\u201339.32; P\u2009=\u20090.001) for diabetes-related mortality versus the optimal controlled group (HbA1c&lt;7%). The poorly controlled group had odds of 1.80 (95% CI, 1.10\u20132.94; P\u2009=\u20090.022) for retinopathy and 2.54 (95% CI, 1.65\u20133.92; P\u2009&lt;\u20090.001) for chronic kidney disease (CKD) versus the optimal controlled group. For individuals with late-onset T2D, the HRs were 0.87 (HR 0.87; 95% CI, 0.54\u20131.40; P\u2009=\u20090.561) for all-cause mortality and 1.24 (95% CI, 0.33\u20134.67; P\u2009=\u20090.751) for diabetes-related mortality compared with the optimal controlled group. The poorly controlled group had odds of 2.12 (95% CI, 1.32\u20133.41; P\u2009=\u20090.002) for retinopathy and 2.30 (95% CI, 1.45\u20133.63; P\u2009=\u20090.001) for CKD versus the optimal controlled group.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Optimal glycemic control was associated with a reduced risk of all-cause mortality, diabetes-related mortality, retinopathy, and CKD in individuals with early-onset T2D; however, in individuals with late-onset T2D, this correlation was limited to lower risks of retinopathy and CKD. These findings suggest that glycemic control strategies should be tailored on the basis of the age of diabetes onset.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0322886","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T17:42:33Z","timestamp":1748022153000},"page":"e0322886","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Divergent impacts of glycemic control on mortality and complications in patients with early-versus late-onset type 2 diabetes: A retrospective cohort study"],"prefix":"10.1371","volume":"20","author":[{"given":"Haipeng","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1274-3903","authenticated-orcid":true,"given":"Na","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"issue":"2","key":"pone.0322886.ref001","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Y Zheng","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"pone.0322886.ref002","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"H Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"pone.0322886.ref003","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00125-017-4390-4","article-title":"Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease","volume":"61","author":"G Jia","year":"2018","journal-title":"Diabetologia"},{"issue":"2","key":"pone.0322886.ref004","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(13)70046-9","article-title":"Diabetes and risk of physical disability in adults: a systematic review and meta-analysis","volume":"1","author":"E Wong","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"pone.0322886.ref005","article-title":"6. Glycemic Targets: Standards of Care in Diabetes-2023","volume":"46","author":"NA ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"pone.0322886.ref006","article-title":"Benefits and harms of intensive glycemic control in patients with type 2 diabetes","volume":"367","author":"R Rodriguez-Gutierrez","year":"2019","journal-title":"BMJ"},{"issue":"10085","key":"pone.0322886.ref007","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/S0140-6736(17)31371-5","article-title":"Type 2 diabetes in adolescents: a severe phenotype posing major clinical challenges and public health burden","volume":"389","author":"R Viner","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"pone.0322886.ref008","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41574-020-0334-z","article-title":"Young-onset type 2 diabetes mellitus - implications for morbidity and mortality","volume":"16","author":"DJ Magliano","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"pone.0322886.ref009","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00125-005-1793-4","article-title":"Peroxisome proliferator-activated receptor gamma coactivator 1 alpha promoter polymorphisms are associated with early-onset type 2 diabetes mellitus in the Korean population","volume":"48","author":"JH Kim","year":"2005","journal-title":"Diabetologia"},{"issue":"1","key":"pone.0322886.ref010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2337\/dc22-1575","article-title":"Incident Early- and Later-Onset Type 2 Diabetes and Risk of Early- and Later-Onset Cancer: Prospective Cohort Study","volume":"46","author":"Y Zhang","year":"2023","journal-title":"Diabetes Care"},{"issue":"1","key":"pone.0322886.ref011","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-8587(17)30186-9","article-title":"Type 2 diabetes in adolescents and young adults","volume":"6","author":"N Lascar","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"pone.0322886.ref012","doi-asserted-by":"crossref","first-page":"634","DOI":"10.2337\/dc13-1545","article-title":"Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial","volume":"37","author":"ME Miller","year":"2014","journal-title":"Diabetes Care"},{"issue":"6","key":"pone.0322886.ref013","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41574-020-0334-z","article-title":"Young-onset type 2 diabetes mellitus - implications for morbidity and mortality","volume":"16","author":"DJ Magliano","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"pone.0322886.ref014","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2337\/dc20-2372","article-title":"Type 2 Diabetes Subgroups, Risk for Complications, and Differential Effects Due to an Intensive Lifestyle Intervention","volume":"44","author":"MP Bancks","year":"2021","journal-title":"Diabetes Care"},{"issue":"8","key":"pone.0322886.ref015","doi-asserted-by":"crossref","first-page":"422","DOI":"10.5694\/mja2.51482","article-title":"Management of type 2 diabetes in young adults aged 18-30 years: ADS\/ADEA\/APEG consensus statement","volume":"216","author":"J Wong","year":"2022","journal-title":"Med J Aust"},{"issue":"12","key":"pone.0322886.ref016","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.2337\/dci18-0052","article-title":"Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association","volume":"41","author":"S Arslanian","year":"2018","journal-title":"Diabetes Care"},{"issue":"24","key":"pone.0322886.ref017","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States","volume":"305","author":"IH de Boer","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"pone.0322886.ref018","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/hep.27047","article-title":"Relationship of hepatitis C virus infection with diabetes in the U.S. population","volume":"60","author":"CE Ruhl","year":"2014","journal-title":"Hepatology"},{"key":"pone.0322886.ref019","article-title":"6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee.","year":"2025","journal-title":"Diabetes Care"},{"issue":"3","key":"pone.0322886.ref020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jamainternmed.2014.7345","article-title":"Potential overtreatment of diabetes mellitus in older adults with tight glycemic control","volume":"175","author":"KJ Lipska","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"6","key":"pone.0322886.ref021","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.annepidem.2017.05.004","article-title":"Evaluation of a methodology to validate National Death Index retrieval results among a cohort of U.S. service members","volume":"27","author":"NA Skopp","year":"2017","journal-title":"Ann Epidemiol"},{"issue":"2","key":"pone.0322886.ref022","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026614","article-title":"Obscuring effect of coding developmental disability as the underlying cause of death on mortality trends for adults with developmental disability: a cross-sectional study using US Mortality Data from 2012 to 2016","volume":"9","author":"SD Landes","year":"2019","journal-title":"BMJ Open"},{"issue":"1","key":"pone.0322886.ref023","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12933-020-01170-w","article-title":"Body mass index and cardiovascular outcomes in patients with acute coronary syndrome by diabetes status: the obesity paradox in a Korean national cohort study","volume":"19","author":"S-J Park","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"9587","key":"pone.0322886.ref024","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(07)61299-9","article-title":"Essential hypertension","volume":"370","author":"FH Messerli","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"pone.0322886.ref025","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"DR Matthews","year":"1985","journal-title":"Diabetologia"},{"issue":"10302","key":"pone.0322886.ref026","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"K Kalantar-Zadeh","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"pone.0322886.ref027","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"AS Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0322886.ref028","article-title":"Associations of Serum Folate and Vitamin B12 Levels With Cardiovascular Disease Mortality Among Patients With Type 2 Diabetes","volume":"5","author":"Y Liu","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"15","key":"pone.0322886.ref029","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"RR Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"23","key":"pone.0322886.ref030","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1806802","article-title":"Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up","volume":"380","author":"PD Reaven","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0322886.ref031","doi-asserted-by":"crossref","first-page":"634","DOI":"10.2337\/dc13-1545","article-title":"Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial","volume":"37","author":"ME Miller","year":"2014","journal-title":"Diabetes Care"},{"issue":"13","key":"pone.0322886.ref032","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2011.404","article-title":"Goals of glycemic control in frail older patients with diabetes","volume":"305","author":"SJ Lee","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"pone.0322886.ref033","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14283\/jfa.2017.39","article-title":"An International Position Statement on the Management of Frailty in Diabetes Mellitus: Summary of Recommendations 2017","volume":"7","author":"AJ Sinclair","year":"2018","journal-title":"J Frailty Aging"},{"issue":"3","key":"pone.0322886.ref034","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10198-010-0224-8","article-title":"Utilities and disutilities for attributes of injectable treatments for type 2 diabetes","volume":"12","author":"KS Boye","year":"2011","journal-title":"Eur J Health Econ"},{"issue":"9","key":"pone.0322886.ref035","doi-asserted-by":"crossref","first-page":"788","DOI":"10.7326\/0003-4819-127-9-199711010-00003","article-title":"Estimated benefits of glycemic control in microvascular complications in type 2 diabetes","volume":"127","author":"S Vijan","year":"1997","journal-title":"Ann Intern Med"},{"issue":"8","key":"pone.0322886.ref036","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.cmet.2021.07.001","article-title":"Cardiovascular disease in diabetes, beyond glucose","volume":"33","author":"RH Eckel","year":"2021","journal-title":"Cell Metab"},{"issue":"5","key":"pone.0322886.ref037","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(15)00044-3","article-title":"Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials","volume":"3","author":"JA Udell","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10354","key":"pone.0322886.ref038","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"M Vaduganathan","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"pone.0322886.ref039","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"N Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"pone.0322886.ref040","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMsa2032271","article-title":"Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018","volume":"384","author":"M Fang","year":"2021","journal-title":"N Engl J Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0322886","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T17:42:43Z","timestamp":1748022163000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0322886"}},"subtitle":[],"editor":[{"given":"Neftali Eduardo","family":"Antonio-Villa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0322886","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}